Evidence map›Paper›PMID 39766077›Full record

ArticleCancers2024

Pan-Cancer Insights: A Study of Microbial Metabolite Receptors in Malignancy Dynamics.

Nikolas Dovrolis, Michail Spathakis, Alexandra R Collins, Varun Kumar Pandey, Muhammad Ikhtear Uddin, Donald D Anderson, Tetiana Kaminska, Vasilis Paspaliaris, George Kolios

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nikolas DovrolisLaboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.ORCID 0000-0003-3832-9939
Michail SpathakisLaboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Alexandra R CollinsPaspa Pharmaceuticals Pty Ltd., Hawthorn East, VIC 3145, Australia.ORCID 0009-0007-2851-1661
Varun Kumar PandeyPaspa Pharmaceuticals Pty Ltd., Hawthorn East, VIC 3145, Australia.
Muhammad Ikhtear UddinPaspa Pharmaceuticals Pty Ltd., Hawthorn East, VIC 3145, Australia.
Donald D AndersonBioGut Technologies Inc., Fort Worth, TX 76104, USA.
Tetiana KaminskaPaspa Pharmaceuticals Pty Ltd., Hawthorn East, VIC 3145, Australia.
Vasilis PaspaliarisPaspa Pharmaceuticals Pty Ltd., Hawthorn East, VIC 3145, Australia.
George KoliosLaboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.ORCID 0000-0002-2066-4782

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesThe role of the gut microbiome in cancer biology has become an increasingly prominent area of research, particularly regarding the role of microbial metabolites and their receptors (MMRs). These metabolites, through the various gut-organ axes, have been proven to influence several pathogenetic mechanisms. This study conducted a comprehensive pan-cancer analysis of MMR transcriptomic profiles across twenty-three cancer types, exploring the mechanisms through which they can influence cancer development and progression.

methodsUtilizing both cancer cell lines from CCLE (Cancer Cell Line Encyclopedia) and human tumor samples from TCGA (The Cancer Gene Atlas), we analyzed 107 MMRs interacting with microbial metabolites such as short-chain fatty acids, bile acids, indole derivatives, and others while studying their interactions with key known cancer genes.

resultsOur results revealed that certain MMRs, such as

conclusionsThese findings suggest that the interactions between microbial metabolites and MMRs may serve as potential biomarkers for cancer diagnosis, prognosis, and therapy, highlighting their therapeutic potential. This study underscores the significance of the microbiota-cancer axis and provides novel insights into microbiome-based strategies for cancer treatment.

Indexed as

biomarkerscancermicrobial metabolite receptorsmicrobiomepan-cancertranscriptomics

Identifiers

PMID39766077
PMCPMC11674037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.